Design and Manufacture of Nanomedicine for Aflax Pump Inhibitors in Clinical Isolates of Methicillin-Resistant Staphylococcus Aureus (MRSA) Bacteria

Abstract

The consequences of this bacterium can be severe. Methicillin is one of these drugs, this drug, like other betalactams, inhibits Trans peptidases by binding to penicillin-binding protein (PBP). It prevents the formation of
peptide glycans in the bacterial cell wall and destroys the bacterial cell wall. Chemical structure modification
has made it resistant to the beta-lactamase enzyme produced by some bacteria. It was made in 1959. Today, it
has been removed from the list of drugs and better alternatives such as cloxacillin and nafsilin are available.
It has a lower spectrum than penicillin but it works well against beta-lactamase-producing organisms
such as Staphylococcus aureus. Design and manufacture of nanoparticles for Aflax pump inhibitors in
methicillin-resistant Staphylococcus aureus bacteria Preparation of BSA-meticillin nano-drug: This was
done using the desolvation method and after ensuring the formation of nanodars using the XRD and FT-IR
spectra, Microdiagnostic antibiogram testing was performed on methicillin-resistant Staphylococcus aureus
and the phenotypic pump activity of all isolates was performed by agar technique containing Ethidium
bromide by vil card method. According to a study, the Nano medicine albumin-methicillin has the highest
inhibition of methylcellulose-resistant Staphylococcus aureus Aflax pump.